BRPI0511874A - derivados da pirrolopiridina - Google Patents

derivados da pirrolopiridina

Info

Publication number
BRPI0511874A
BRPI0511874A BRPI0511874-3A BRPI0511874A BRPI0511874A BR PI0511874 A BRPI0511874 A BR PI0511874A BR PI0511874 A BRPI0511874 A BR PI0511874A BR PI0511874 A BRPI0511874 A BR PI0511874A
Authority
BR
Brazil
Prior art keywords
derivatives
pyrrolopyridine derivatives
diseases
indirectly
decrease
Prior art date
Application number
BRPI0511874-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew John Eatherton
Gerard Martin Paul Giblin
Matthew Russell Johnson
William Leonard Mitchell
Alcide Perboni
Brian Peter Slingsby
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412908A external-priority patent/GB0412908D0/en
Priority claimed from GB0424950A external-priority patent/GB0424950D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0511874A publication Critical patent/BRPI0511874A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0511874-3A 2004-06-09 2005-06-07 derivados da pirrolopiridina BRPI0511874A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0412908A GB0412908D0 (en) 2004-06-09 2004-06-09 Compounds
GB0424950A GB0424950D0 (en) 2004-11-11 2004-11-11 Compounds
PCT/EP2005/006182 WO2005121140A1 (en) 2004-06-09 2005-06-07 Pyrrolopyridine derivatives

Publications (1)

Publication Number Publication Date
BRPI0511874A true BRPI0511874A (pt) 2008-01-15

Family

ID=34969264

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511874-3A BRPI0511874A (pt) 2004-06-09 2005-06-07 derivados da pirrolopiridina

Country Status (25)

Country Link
US (1) US7589206B2 (enExample)
EP (1) EP1753764B1 (enExample)
JP (1) JP2008501758A (enExample)
KR (1) KR20070034049A (enExample)
AR (1) AR050158A1 (enExample)
AT (1) ATE412651T1 (enExample)
AU (1) AU2005251913A1 (enExample)
BR (1) BRPI0511874A (enExample)
CA (1) CA2569887A1 (enExample)
DE (1) DE602005010698D1 (enExample)
DK (1) DK1753764T3 (enExample)
ES (1) ES2317244T3 (enExample)
HR (1) HRP20090034T3 (enExample)
IL (1) IL179603A0 (enExample)
MA (1) MA28686B1 (enExample)
MX (1) MXPA06014471A (enExample)
NO (1) NO20070067L (enExample)
PE (1) PE20060430A1 (enExample)
PL (1) PL1753764T3 (enExample)
PT (1) PT1753764E (enExample)
RU (1) RU2006147278A (enExample)
SI (1) SI1753764T1 (enExample)
TW (1) TW200611695A (enExample)
UY (1) UY28945A1 (enExample)
WO (1) WO2005121140A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
DK1753764T3 (da) 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
KR20220084426A (ko) † 2004-07-28 2022-06-21 다케다 야쿠힌 고교 가부시키가이샤 피롤로〔2,3-ｃ〕피리딘 화합물, 그 제조 방법 및 용도
DK1784404T3 (da) * 2004-09-03 2012-02-13 Yuhan Corp Pyrrolo[2,3-c]pyridinderivater samt fremgangsmåder til deres fremstilling
TW200734335A (en) * 2005-08-09 2007-09-16 Glaxo Group Ltd Compounds
GB0516379D0 (en) * 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
CA2643863A1 (en) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US20100041672A1 (en) * 2007-03-21 2010-02-18 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2010113834A1 (ja) 2009-03-30 2010-10-07 アステラス製薬株式会社 ピリミジン化合物
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
TWI482622B (zh) 2010-07-29 2015-05-01 Astellas Pharma Inc Shrinkage pyridine compounds
WO2013140342A1 (en) * 2012-03-19 2013-09-26 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
BR112015032330B1 (pt) 2013-06-26 2019-01-22 Abbvie Inc. carboxamidas primárias como inibidores de bkt
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN113271938A (zh) * 2018-11-30 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113245B1 (en) * 1982-12-29 1989-03-15 Kureha Kagaku Kogyo Kabushiki Kaisha Cephalosporin derivatives
CA2031927A1 (en) 1989-12-27 1991-06-28 Imperial Oil Limited Method for improving the activity maintenance of a plasma initiator
WO1991009598A1 (en) 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW263504B (enExample) 1991-10-03 1995-11-21 Pfizer
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
CO4340691A1 (es) 1994-02-18 1996-07-30 Boehringer Ingelheim Pharma 2-HETEROARIL-5,11-DIHIDRO-6H-DIPIRIDO(3,2-b:2´, 3´ -e) (1, 4)-DIAZEPINAS .
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
JPH0920779A (ja) 1995-05-01 1997-01-21 Japan Tobacco Inc 縮合ヘテロ５員環アゼピン化合物類及びその医薬用途
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0931872B1 (de) 1998-01-23 2003-04-09 Voith Paper Patent GmbH Verfahren zur Entfernung von feinen Verunreinigungen aus einer Faserstoffsuspension
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1117397A1 (en) 1998-08-31 2001-07-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
EP1171125A1 (en) 1999-03-10 2002-01-16 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1165075A4 (en) 1999-03-10 2002-04-10 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS GONADOLIBERINE'S ANTAGONISTS
AU3514200A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1165076A4 (en) 1999-03-10 2002-05-15 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS GONADOLIBERINE'S ANTAGONISTS
WO2000053179A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU3868500A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
CA2390948A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
AR028385A1 (es) 2000-04-28 2003-05-07 Acadia Pharm Inc Agonistas muscarinicos
CZ20023544A3 (cs) 2000-04-28 2004-07-14 Baxter Healthcare Sa Deriváty 2-acylindolu a jejich použití jako protinádorové činidlo
ES2262674T3 (es) 2000-08-14 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CA2421510A1 (en) 2000-09-06 2002-03-14 Hui Cai A method for treating allergies using substituted pyrazoles
US6369032B1 (en) 2000-09-06 2002-04-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2004520365A (ja) 2001-01-17 2004-07-08 アミュラ テラピューティクス リミテッド クルジパインおよび他のシステインプロテアーゼの阻害剤
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
KR20030079979A (ko) 2001-02-02 2003-10-10 브리스톨-마이어스스퀴브컴파니 치환된 아자인돌옥소아세틱 피페라진 유도체의 조성물 및항바이러스 활성
US6951848B2 (en) 2001-03-12 2005-10-04 Millennium Pharmaceuticals, Inc., Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
DE60217669D1 (de) 2001-05-14 2007-03-08 Bristol Myers Squibb Co Substitutierte pyrazinone, pyridine und pyrimidine als corticotropin-releasing-factor liganden
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003009852A1 (en) 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors
DE10143079A1 (de) 2001-09-03 2003-05-15 Zentaris Ag Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
DK1438310T3 (da) 2001-10-19 2007-03-26 Transtech Pharma Inc Beta-carbolin-derivater som PTP-inhibitorer
DE10152306A1 (de) 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
US20050124626A1 (en) 2002-03-27 2005-06-09 Johnson Christopher N. Novel compounds
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US7427616B2 (en) 2002-08-06 2008-09-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (TEK) activity
US20060247261A1 (en) 2002-08-21 2006-11-02 Eatherton Andrew J Pyrimidine compounds
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
TW200418498A (en) 2002-09-30 2004-10-01 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
FR2845388B1 (fr) 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
CN100482662C (zh) 2003-02-14 2009-04-29 惠氏公司 作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
DK1753764T3 (da) 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater

Also Published As

Publication number Publication date
DK1753764T3 (da) 2009-02-16
PL1753764T3 (pl) 2009-04-30
SI1753764T1 (sl) 2009-02-28
RU2006147278A (ru) 2008-07-20
PT1753764E (pt) 2009-01-28
PE20060430A1 (es) 2006-05-25
NO20070067L (no) 2007-02-09
JP2008501758A (ja) 2008-01-24
DE602005010698D1 (de) 2008-12-11
WO2005121140A1 (en) 2005-12-22
ATE412651T1 (de) 2008-11-15
AR050158A1 (es) 2006-10-04
HRP20090034T3 (en) 2009-03-31
IL179603A0 (en) 2007-05-15
EP1753764B1 (en) 2008-10-29
MA28686B1 (fr) 2007-06-01
AU2005251913A1 (en) 2005-12-22
TW200611695A (en) 2006-04-16
ES2317244T3 (es) 2009-04-16
US20070219229A1 (en) 2007-09-20
HK1104175A1 (en) 2008-01-04
EP1753764A1 (en) 2007-02-21
UY28945A1 (es) 2006-01-31
US7589206B2 (en) 2009-09-15
KR20070034049A (ko) 2007-03-27
MXPA06014471A (es) 2007-03-21
CA2569887A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
BRPI0511874A (pt) derivados da pirrolopiridina
BR0314635A (pt) Derivados de piridina como moduladores de receptores de cb2
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
DE60309739D1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
HRP20070076A2 (en) Pyrimidine derivatives
BR122020010667B8 (pt) inibidores de quinase, seus usos, e composição farmacêutica
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20084352L (no) Dimerer av artemisininderivater, fremstilling derav og terapeutisk anvendelse derav
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
AU2003260436A1 (en) Pyrimidine compounds
EA200702253A1 (ru) Фармацевтическая композиция
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.